ConductScience.org, home
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
API referenceFor AI assistants

Trial · NCT01587703

Results by group3,672

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 3,672

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 2 mg QDAny AE3Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 4 mg QDAny AE4Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 8 mg QDAny AE1Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 16 mg QDAny AE3Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 30 mg QDAny AE3Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 60 mg QDAny AE9Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 80 mg QDAny AE31Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 100 mg QDAny AE9Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 2 mg QDAny SAE0Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 4 mg QDAny SAE2Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 8 mg QDAny SAE0Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 16 mg QDAny SAE0Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 30 mg QDAny SAE1Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 60 mg QDAny SAE2Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 80 mg QDAny SAE21Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QDPart 1: GSK525762 100 mg QDAny SAE3Participants
Number of Participants With AEs and SAEs-Part 1 BIDPart 1: GSK525762 20 mg BIDAny AE4Participants
Number of Participants With AEs and SAEs-Part 1 BIDPart 1: GSK525762 30 mg BIDAny AE10Participants
Number of Participants With AEs and SAEs-Part 1 BIDPart 1: GSK525762 40 mg BIDAny AE5Participants
Number of Participants With AEs and SAEs-Part 1 BIDPart 1: GSK525762 20 mg BIDAny SAE0Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01587703/results

API referenceFor AI assistants